Thursday, January 2, 2020

Updates in hematology/ oncology

Studies say that anemia is an early and multifactorial complication of multiple myeloma and has been reported to occur in over two thirds of all patients. It also has a negative impact on the quality of patients’ lives and is an independent predictor of poor survival. It is also said that in patients with multiple myeloma, anaemia is usually normocytic and normochromic but can be macrocytic and the anaemia is manifested as a hemoglobin level between 8 and 10 g/dL, while approximately 10% have a value below 8 g/dL. Serum iron levels are usually normal to mildly low; serum ferritin is high and hemosiderin is significant in bone marrow macrophages, consistent with patterns similar to anemia of chronic disease. It is also said that chemotherapy-responsive patients, with or without exogenous erythropoietin administration, often see a normalization of their haemoglobin levels with a resultant improvement in quality of life, despite the impact of patients’ ages and stages of disease.

To discuss more such interesting findings in hematology and oncology, join us at the best hematology, oncology, cancer, leukemia, lymphoma and blood conferences organized. To know more info, PS: Hematology & Oncology congress
 

No comments:

Post a Comment